Dr. Arinder Sihota, PhD
In December 2010, pharmacovigilance legislation was updated through amendments to Regulation (EC) No 726/2004 and Directive 2001/83/EC. This was followed by the addition of Commission Implementing Regulation (EU) No 520/2012 in June 2012. The main objective of these changes is to allow for better detection of new or changing safety issues, enabling rapid action to protect public health.
The main changes that have been brought about by these legislation amendments, and are effective from November 2017, are depicted in:
- Updated Good Pharmacovigilance Practice, GvP Module VI, Management and Reporting of Adverse Reactions to Medicinal Products (currently in draft format)
- Updated Good Pharmacovigilance Practice, GvP Module IX, Signal Management (currently in draft format)
Below we describe some of the key elements of the anticipated changes and action required for readiness.
Reporting of ICSRs in the EU to the EMA only, and removal of the interim arrangements
This intends to simplify reporting within the EU. The time taken to triage a case to determine its recipient(s), including competent authority specific identifiers in Eudravigilance, will decrease. In addition, Marketing Authorisation Holders (MAH’s) will no longer be required to carry out country specific registrations and/or testing in order to set up organisation identifiers.
Although it is expected that reporting will in theory be simplified, it is advisable to obtain confirmation from competent authorities if any existing additional paper or portal reporting, should cease, or if this will be a continued national requirement.
Receipt of all lCSRs from Eudravigilance in ISO ICSR E2B (R3) format only
MAHs can continue to submit ICSRs in E2B(R2) format, however, any cases downloaded from Eudravigilance will be in E2B(R3) format only. This of course requires system updates for compliance. MAH’s are advised to work with safety database providers to ensure full E2B R3 compatibility. A contingency plan should also be developed to ensure a validated conversion tool is available for use immediately should it be required, to ensure the readability of the files.
Reporting of all non-serious EEA cases to EudraVigilance within 90-days of receipt
This will increase the burden of reporting. Currently only seven EEA NCAs require non-serious cases. The burden will vary by product and therefore per company and will inevitably demand extra resource for submissions via EVWeb.
Signal detection in the EudraVigilance Data Analysis System (EVDAS) and ICSR download functionality by MAHs
This will allow MAHs access to a greater level of detail on applicable ICSRs than is currently supplied. It will also mean that MAHs will become responsible for the regular review and analysis of the Eudravigilance database with regards to signal detection.
The frequency of signal detection activities will depend on the nature of the product. For newly licensed products we expect a two weekly review cycle; for older, long-available products this may be stretched to six monthly reviews. The frequency should be documented and justified in signal management documentation.
MAH’s will have the option to create standard searches and there exists an ability to save customised searches within the system, however, depending on the nature of the product and the number of events this activity is likely to be resource intensive. From 01-Jun-2017, the EMA Registrations team will contact QPPVs to enable EVDAS user registration and access.
Use of ISO IDMP terminologies, once available
As a consequence of the legal requirements set out in the legislation, the xEVPRM will be replaced by the ISO IDMP format. The use of these standards is mandated by the EU legislation (Commission Implementing Regulation (EU) No 520/2012). ISO IDMP format is an extension of the current information available in the xEVMPD.
In addition, some conceptual differences are introduced which will need to be taken into account while performing the data migration. Practically, there will be a phased implementation of ISO IDMP standards, termed SPOR (Substances, Products, Organisations, Referentials), allowing lessons learnt during each phase to be applied in subsequent phases. SPOR is expected to become mandatory from January 2018.
The EMA have now announced a successful result from the independent EudraVigilance audit and a favourable recommendation from the PRAC, thus confirming that the EMA is on track, and the new EudraVigilance system is expected to be released 22 November 2017. Although we are still awaiting news on the GvP modules, and the exact changes described above and any others will only definitively be known once they are released in their final form.
Webinar: Ensuring pharmacovigilance compliance and robust oversight at the affiliate level
Explore the benefits of adopting an outsourced model for pharmacovigilance.
Getting ready
Our expert cross-functional Pharmacovigilance Regulatory Change Management team is attending all relevant EMA stakeholder meetings and training to ensure we are aware of information, as it is released. We are working on an intense implementation and roll-out plan and accordingly, are on track to have the extra resources, procedural updates, training and system changes in place in advance of the stipulated timelines.
If you require assistance in understanding the new regulations and how they impact your business, we are available to support you and your business throughout the transition period. Contact us here.
In this section
-
Digital Disruption
-
Digital Disruption whitepaper
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Digital Disruption whitepaper
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Blended solutions insights
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel